Patent ID: 8987221
Filing Date: 2015-03-24
Classification: A61K,A61P,C12N,Y02A

Abstract:
1. A method for therapeutically treating a mammal having a disease having an autoimmune or inflammatory component where inhibition of tumor necrosis factor alpha (TNF) would be beneficial, such method comprising administering to the mammal an immune regulatory oligonucleotide (IRO) compound in combination with an anti-inflammatory agent that inhibits TNF in a pharmaceutically effective amount wherein the IRO compound comprises an oligonucleotide having the structure wherein: CG is an oligonucleotide motif that is C*pG, C*pG* or CpG*, wherein C is cytosine, C* is a cytosine nucleotide derivative, G is guanosine and G* is a guanosine nucleotide derivative; N N N provided that the IRO compound contains less than 3 consecutive guanosine nucleotides; wherein the oligonucleotide motif would be immune stimulatory but for the one or more modified nucleotides that suppresses the activity of the oligonucleotide motif; wherein the IRO compound is an antagonist of TLR7, TLR8 and/or TLR9; wherein the IRO compound is not an antisense oligonucleotide; wherein the IRO compound potentiates the activity of the anti-inflammatory agent that inhibits TNF; and wherein m is a number from 0 to about 30.